New weight loss pill was more effective than semaglutide in trial | The IndependentNotifications can be managed in browser preferences.Jump to contentIndependentSwipe for next articleIndependent Bulletin homepageDownload ourSocial PartnerWe are 8 logo (opens in a new tab)AllNewsSportCultureLifestyleElla PickoverThursday 26 February 2026 12:01 GMTRelated: Eli Lilly launches new weight loss drug pillA new once-a-day weight loss pill, orforglipron, has been hailed as an “important advancement” in type 2 diabetes care following a new study.The study compared orforglipron against oral semaglutide, an existing tablet version of a GLP-1 receptor agonist, finding it superior for blood sugar reduction and weight loss.Patients taking orforglipron lost between six and eight per cent of their body weight, compared to four to five per cent for those on semaglutide.A key advantage of orforglipron is that it can be taken without restrictions on food or water intake, unlike oral semaglutide, which requires an empty stomach.While more patients on orforglipron reported gastrointestinal side effects, experts from Diabetes UK welcomed the findings, highlighting the importance of diverse treatment options.In fullResearchers discover benefits of once-a-day weight loss pillThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in